Coenzyme Q (CoQ) is present in all cells and membranes and in addition to be a member of the mitochondrial respiratory chain it has also several other functions of great importance for the cellular metabolism. This review summarizes the findings available to day concerning CoQ distribution, biosynthesis, regulatory modifications and its participation in cellular metabolism. There are a number of indications that this lipid is not always functioning by its direct presence at the site of action but also using e.g. receptor expression modifications, signal transduction mechanisms and action through its metabolites. The biosynthesis of CoQ is studied in great detail in bacteria and yeast but only to a limited extent in animal tissues and therefore the informations available is restricted. However, it is known that the CoQ is compartmentalized in the cell with multiple sites of biosynthesis, breakdown and regulation which is the basis of functional specialization. Some regulatory mechanisms concerning amount and biosynthesis are established and nuclear transcription factors are partly identified in this process. Using appropriate ligands of nuclear receptors the biosynthetic rate can be increased in experimental system which raises the possibility of drug-induced upregulation of the lipid in deficiency. During aging and pathophysiological conditions the tissue concentration of CoQ is modified which influences cellular functions. In this case the extent of disturbances is dependent on the localizaion and the modified distribution of the lipid at cellular and membrane levels. D
Coenzyme Q (CoQ) was isolated and characterized by Festenstein et al. in 1955 [1] and it was established in 1957 by Crane et al. [2] that this compound functions as a member of the mitochondrial respiratory chain. Wolf et al. [3] determined its complex structure in 1958. CoQ was found to be an unusual lipid since the redox active benzoquinone ring is connected to a long isoprenoid side chain, requiring specific placements in a biological membrane. At this time only the redox function of this lipid was studied while its function as an antioxidant was investigated mainly during the past 15 years. In the initial period, the concept of CoQ distribution and synthesis was attributed exclusively to the inner mitochondrial membrane. This appeared to be reasonable since the only known function at this time was shuttling electrons from complexes I and II to complex III in the mitochondrial electron transfer system. During the 1960s the obligatory role of CoQ in the respiratory chain was proven by several facts, such as depletion and reincorporation of the lipid into submitochondrial particles causing inactivation and reactivation of NADH and succinate dehydrogenas activities [4] . In 1975 Mitchell [5] proposed the protonmotive Q cycle, the cyclic electron transfer pathway through complex III involving ubisemiquinone, a proposal generally accepted. The role of CoQ in the mitochondrial respiratory chain and associated oxidative phosphorylation is studied in great details by many investigators and is not discussed here. There are recent and excellent reviews about this subject which are recommended to consult [6] [7] [8] [9] .
Functions of CoQ
In addition to its central role in the mitochondrial respiratory chain, CoQ is now involved in a number of aspects of cellular metabolism and we can expect that several new functions will also appear in the near future (Table 1 ).
The plasma membrane redox system
The plasma membrane of eukaryotic cells contains an NADH oxidase (NOX) that is involved in the transfer of electrons across the membrane (Fig. 1 ). The name of this enzyme was given in the initial period of studies, when it was believed that the function of the enzyme is the oxidation of the externally added NADH. The NOX protein is not a transmembranous protein but is located at the external surface of the plasma membrane [10] . It has both hydroquinone (or NADH) oxidase and protein-disulfide-thiol interchange activities that have been shown to respond to hormones and growth factors [11, 12] . The NOX protein is not related to the NADPH oxidase found in neutrophils, which is not dependent of CoQ [13] . At the cytosolic surface, a quinone reductase is present that catalyzes the reduction of CoQ in the presence of NADH [14] . This system together with the enzymatic mechanisms discussed in Section 7 are responsible for regeneration of cellular reduced CoQ. The participation of CoQ in the plasma membrane electron transport was shown by the fact that the NOX activity was inhibited by removal of CoQ with heptane and reconstitution of the activity by CoQ addition [15] . Several terminal electron acceptors have been suggested, such as molecular oxygen, protein disulfides or ascorbyl radicals [15 -17] .
The function of NOX is proposed to be related to the control of cell growth and differentiation as well as maintaining extracellular ascorbate in reduced form [18, 19] . Another possibility is that the CoQ-dependent NOX is involved in the regulation of the cytosolic NAD + /NADH ratio. In fact, Larm et al. [20] and Lawen et al. [21] showed that U 0 cells, lacking mitochondrial DNA, accumulate NADH as a result of glycolytic production of ATP and that the plasma membrane oxidoreductase system is able to reoxidize the NADH in these cells. Finally, Crane et al. [22] proposed yet another two functions for CoQ in the plasma membrane electron transfer system. First, the redox state of CoQ may act to control a tyrosine kinase in a manner analogous to that found in Escherichia coli [23] . Second, oxidation of the semiquinone in the plasma membrane could generate H 2 O 2 and it has been shown that activation of peroxide generation, by for instance xanthine oxidase, induces tyrosine kinase and early gene expression [24, 25] .
Recently it was also suggested that lysosomes contain an NADH-dependent CoQ reductase involved in translocation of protons into the lysosomal lumen [26] . Apparently, at this location the reduction of CoQ occurs in two subsequent one-electron transfer steps involving FAD and cytochrome b 5 with molecular oxygen as the terminal electron acceptor. Though intriguing, further research will be necessary to define the function of this CoQ-dependent lysosomal reductase.
Antioxidants and generation of reactive oxygen species (ROS)
Eighty percent of the normal mammalian oxygen consumption occurs in mitochondria, of which 80% is coupled to ATP production [27, 28] . ROS account for 1 -2% of the Table 1 Functions of coenzyme Q . Participation as electron carrier in the mitochondrial respiratory chain . Participation in extra-mitochondrial electron transport (PLM a , lysosomes) . Endogenously synthesized, lipid-soluble antioxidant . Regulation of mitochondrial permeability transition pores . Required for activation of mitochondrial uncoupling proteins . Regulation of the physicochemical properties of membranes . Modulation of the amount of h2-integrins on the surface of blood monocytes . Improvement of endothelial dysfunction (probably by increasing nitrogen oxide) . Oxidation of sulfide (in yeast) . Introduction of disulfide bonds (in bacteria) a Plasma membranes. Fig. 1 . Schematic representation of the CoQ-dependent trans-plasma membrane electron transport. At the cytosolic side of the plasma membrane, a quinone reductase is present that reduces CoQ to ubiquinol (CoQH 2 ). CoQH 2 shuttles the electrons to the NOX that is able to reduce extracellular ascorbyl radicals (Asc), produce superoxide (O 2 À ), reduce O 2 to water and reduce protein disulfides. The figure is adopted from Morré et al. [317] .
oxygen consumed by mitochondria and this compartment is considered to be the major source of O 2 S À and H 2 O 2 production in the cell [29, 30] . The leakage of electrons from the respiratory chain result in a 5 -10-fold higher steady-state concentration of O 2 À in the mitochondrial matrix than in the cytosolic and nuclear spaces [31] . The formation of mitochondrial ROS is dependent on the state of respiration, i.e. in state 4, when the mitochondrial membrane potential is high and the ADP levels are low, the production of ROS is high. In state 3, when the membrane potential is low and the ADP concentration is high, the production of ROS is low. Another source of ROS is the production of H 2 O 2 by monoamine oxidase in mitochondria, the various flavin oxidases in peroxisomes and the leakage of electrons from cytochrome P-450 in the endoplasmic reticulum (ER) [32 -34] .
The free radicals formed in the cell are able to damage lipids, proteins and DNA, a concept known as oxidative stress. Lipid peroxidation is by far the most studied process and the initiation occurs by abstraction of a hydrogen atom from a methylene group of a polyunsaturated fatty acid (PUFA). The results of lipid peroxidation are carbon-centered free radical, peroxyl radical, lipid hydroperoxide, alkoxyl radical and degradation to hydrocarbons, alcohols, ethers, epoxides and aldehydes. The aldehydes formed are relatively long-lived and can therefore diffuse a longer distance from their site of origin than free radicals. Since they can also react with macromolecules, they further contribute to the damage caused by lipid peroxidation. A secondary defense mechanism involving phospholipase A 2 removes the peroxidized fatty acid that can be replaced by new fatty acids [35] . If the removed fatty acid is not replaced completely, the lysophospholipid formed acts as a detergent and damages the membrane. Other defense systems are the glutathione peroxidases, especially the phosphohydrolipid glutathione peroxidase, that scavenge the lipid hydroperoxides formed during lipid peroxidation [36] .
Protein oxidation usually occurs at certain amino acid residues of a particular protein. Although some amino acids are more prone to oxidation than others, the selectivity of the initiating attack is attributed to protein-bound transition metals that react with ''weak ROS'' and form hydroxyl radicals at the metal-binding site [37, 38] . The subsequent abstraction of a hydrogen atom and formation of peroxyl radicals and hydroperoxides are similar to lipid peroxidation. Propagation can occur within the protein, to another protein or to lipids. Oxidation of membrane proteins can also take place by lipid-derived free radicals [39] . Oxidized proteins are recognized by specific proteases and completely degraded to amino acids. Thus, replacement by de novo synthesis of proteins is the only repair mechanism [40, 41] .
DNA oxidation by ROS is believed to be dependent on transition metals in a similar manner to protein oxidation [42] . Due to the relatively high production of ROS in mitochondria, lack of protective histones and limited ability of repair, mitochondrial DNA has about 10-fold higher oxidative damage than nuclear DNA [43] . Oxidized DNA is repaired by two enzymatic mechanisms, removal and subsequent replacement of single oxidized deoxyribonucleotides and/or excision of 25 -32 nucleotides long oligomers of oxidized bases that are replaced by DNA polymerase and subsequently sealed by DNA ligase [44] .
Antioxidants are enzymes and nonenzymatic agents that can prevent the formation of, or remove ROS. Antioxidant enzymes include superoxide dismutase and various peroxidases such as glutathione peroxidase, catalase, thioredoxin reductase and peroxiredoxin [45, 46] . Nonenzymatic agents include vitamins C and E, carotenoids, glutathione, a-lipoic acid, flavinoids and the reduced form of CoQ (CoQH 2 ) that all rely on a mechanism of regeneration in the cell. CoQH 2 was originally described to inhibit lipid peroxidation in vitro using submitochondrial particles [47, 48] . It is now well established that CoQH 2 is able to prevent lipid peroxidation in most subcellular membranes [49] . The lipid plays an important role as antioxidant also in the circulation [50, 51] . Since CoQH 2 is oxidized during lipid peroxidation, reductive regeneration is a requirement for participation in antioxidative reactions. Mitochondrial CoQH 2 is efficiently regenerated by the respiratory chain and is normally kept in a highly reduced state [52] . As it will be discussed later (Section 7), the cell has effective systems to reduce CoQ at all intracellular locations. Studies performed on the mechanism of its action suggest that CoQH 2 acts by affecting the initiation process and preventing the formation of lipid peroxyl radicals (LOO) while vitamin E acts by quenching these radicals (Fig. 2) [53] . It appears that CoQH 2 reduces the initiating perferryl radical with the formation of ubisemiquinone and H 2 O 2 . It is also possible that it eliminates LOO directly; furthermore, it is established that CoQH 2 regenerates vitamin E from the a-tocopheroxyl radical. This appears to be favored in comparison with the alternative, which is regeneration by ascorbate. Lipid solubility, efficient continuous regeneration and involvement both in the initiation and propagation steps of lipid peroxidation explain why CoQ is considered as a highly efficient antioxidant against radicals produced in biological membranes. In fact, it appears that this antioxidant is considerably more efficient than vitamin E [54] .
When phosphatidylcholine liposomes are oxidized with a water-soluble radical initiator in the presence of ascorbate, a-tocopherol (a-T) and CoQ the antioxidants are consumed in the order: ascorbate -CoQ -a-T [55] . When a lipidsoluble radical initiator is used, the antioxidants are consumed in the order: CoQ -ascorbate -a-T. Thus, a-T is efficiently spared in both cases and this kinetic data showed that the a-tocopheroxyl radical formed is reduced by CoQH 2 . This sparing effect of a-T by CoQH 2 has also been observed in low density lipoprotein (LDL) [56, 57] . The fact that the antioxidant function of CoQH 2 is not dependent on the presence of a-T, is evident from the fact that submitochondrial particles containing CoQ are protected from lipid peroxidation also in the absence of a-T [58] .
Oxidation of membrane proteins can also be prevented by CoQH 2 [39, 59, 60] . DNA oxidation measured by 8-hydroxydeoxyguanosine formation in rat liver mitochondria and DNA strand breaks in human lymphocytes is also prevented by CoQH 2 administration both in vitro and in vivo [49, 61, 62] . Finally, reduced plastoquinone found in plant chloroplast membranes exerts an antioxidant activity similar to that shown for CoQH 2 [63] .
Uncoupling proteins (UCPs)
UCPs are situated in the inner mitochondrial membrane and can translocate H + from the outside to the inside of the mitochondria. Thus, the proton gradient built by the respiratory chain is uncoupled from oxidative phosphorylation and heat rather than energy is produced [64 -66] . UCPs occur in many animal and plant cells and form a subfamily of the mitochondrial carrier family. Five UCPs (1-5 in humans) are known and UCP1 is the most well characterized, present in brown adipose tissue where it participates in thermogenesis [67, 68] . In other tissues where uncoupling is not a dominant feature, UCPs occur only in small amounts. UCP2 is expressed in most animal tissues and UCP3 is expressed most abundantly in human skeletal muscle [69] . In addition to thermogenesis, UCPs could be involved in suppression of oxygen radicals. There are also suggestions that altered UCP expression could be related to human diseases, such as obesity and diabetes.
Recently Echtay et al. [70, 71] showed that CoQ is an obligatory cofactor for UCP function using bacterial overexpressed UCP1, -2 and -3 in liposomes. These liposomes were unable to transport H + in the absence of CoQ and H + transport was activated when CoQ was added to the membranes in the presence of fatty acids. The CoQ-stimulated activity could be inhibited by addition of ATP. Full activation of UCPs in reconstituted vesicles was achieved with CoQ/phospholipid ratio of 1:300 and CoQ/UCP ratio of 80:1. It was proposed that CoQ interact with UCP in the hydrophobic bilayer since maximal activity was achieved with CoQ10 and hydrophilic CoQs with none or a short isoprenoid side chain (0-2 isoprenes) were ineffective to activate UCPs (Fig. 3 ) [71] . It was also suggested that the interaction between CoQ and UCP3 occurred closer to the membrane surface, since UCP3 retains some of its activity with hydrophilic CoQs. Thus, CoQ, but not ubiquinol, could in an active way subtract H + from fatty acids and deliver them to the H + acceptor group of the UCP. Consequently, the oxidized form of CoQ has to be present in mitochondria for this activation.
The mitochondrial permeability transition pore (PTP)
The inner membrane of the mitochondria has a low permeability to ions and solutes in order to permit energy conservation in the form of an electron and a pH gradient over the membrane. In order to facilitate trans-membraneous transport, the inner membrane contains a number of macromolecule transporters and ion channels. However, under in vitro accumulation of Ca 2+ , the mitochondria can undergo a generalized increase of permeability of the inner membrane, known as permeability transition. This enable macromolecules with a size of approximately 1500 Da to cross the membrane causing collapse of the protonmotive force, ) is delivered from a fatty acid (FA-CO 2 H) to the UCP with the assistance of CoQ in the inner mitochondrial membrane. The UCP subsequently translocates the proton to the matrix. The figure is based on the proposals from Echtay et al. [71] . disruption of ionic status, loss of pyridine nucleotides, and hydrolysis of ATP [72] . The permeabilization of the membrane is due to the opening of an inner mitochondrial complex, the PTP. The PTP behaves like a voltage-dependent channel, favoring a closed conformation at high membrane potentials and an open conformation at low membrane potentials. Upon Ca 2+ accumulation, more than 40 classes of unrelated factors can modulate the PTP to open or close, including the mitochondrial membrane potential, the matrix pH, cyclosporin A, phosphate, oxidized glutathione and pyridine nucleotides derived from oxidative stress. The permeability transition has been proposed to be an early key event in several models of apoptosis causing activation of the caspase cascade through release of cytochrome c [73] . Under physiological conditions, it is thought that the PTP serves as a fast Ca 2+ release channel in the mitochondria [74, 75] .
Several analogues of CoQ have been shown to affect the PTP [76 -78] . They all contain a benzoquinone ring with either none or a short (0-2 isoprenes) saturated or unsaturated side chain and can be divided into three functional classes; inhibitors, inducers and inactive quinones that counteract the effects of both the inhibitors and the inducers. The structure -function correlation of these analogues has suggested that minor changes in the isoprenoid side chain can turn an inhibitor into an inducer and that the methoxy groups are not essential for activity [77] . It has therefore been suggested that quinones modulate the PTP through a common binding site rather than through redox reactions. CoQ10 seems also to prevent PTP opening, since it was shown in a recent study that CoQ10 is able to counteract mitochondrial membrane potential depolarization, ATP depletion, cytochrome c release, caspase-9 activation and DNA fragmentation in keratinocytes upon apoptotic stimuli [79] . However, the actual PTP opening and the mechanism of action by CoQ10 were not investigated in this study.
Lymphocytes and monocytes
Isolated human blood lymphocytes increase their CoQ10 content several folds upon incubation with liposomes containing CoQ10 [61] . Supplementation of human subjects with 300 mg/day CoQ10 for 1 week elevates the lipid content in lymphocytes from 14 to 32 pmol/10 6 cells [62] . In vitro supplementation was proved to enhance DNA resistance for hydrogen peroxide-induced oxidation but it did not inhibit DNA strand break formation [61] . The in vivo enrichment of CoQ10 in lymphocytes was shown to inhibit oxidative DNA damage and enhanced the DNA repair enzyme activity in these lymphocytes [62] . Two months of CoQ10 administration to humans appears to affect the qualitative distribution of cells by increasing the ratio of T4/T8 lymphocytes in a significant extent [80, 81] . An increase in the number of lymphocytes was also observed in a study after 3 months of dietary CoQ10 supplementation in humans [82] . An investigation of a healthy population in ages 90 -106 years indicated that in women NK cell cytotoxicity is positively associated with plasma CoQ10 concentration [83] .
Blood components are considered to play an important role during development of atherosclerosis. Monocytes initially attach and accumulate on the endothelial cells which are covering the arterial wall and appear as macrophages after migration [84, 85] . According to this concept, the accumulation of oxidized cholesterol in macrophages is the main reason for the development of the atherosclerotic plaque. The process of monocyte -endothelial interaction is mediated by several substances and cellular components. One of the main factors is the adhesion molecules, the integrins, which upon stimulation are recruited to the surface of the cell [86, 87] . Administration of CoQ10 to humans results in an uptake into monocytes but not into granulocytes ( Table 2 ) [88] . Interestingly, a-T content is elevated in both monocytes and granulocytes. The phospholipid fatty acid composition displays a very selective modification, appearing as an increase of the arachidonic acid content. When the basal and stimulated levels of h2-integrin CD11b and complement receptor CD35 were investigated, the expression of these receptors on the cell surface was found to be decreased considerably. Again, these changes were restricted only to monocytes. The antiatherogenic effect of CoQ10 was established earlier from studies on apolipoprotein E deficient mice fed a high fat diet [89, 90] . It was shown in these investigations that upon CoQ administration, in addition to the increased aortic CoQ and a-T levels and the decreased concentration of hydroperoxides in the atherosclerotic lesions, there was a clear decrease of lesion size in the whole aorta. This could not be attributed solely to an antioxidative effect since several oxidative stress markers did not decrease in this study. The decrease of adhesion factors upon dietary CoQ administration appears to inhibit the recruitment of monocytes to the atherosclerotic lesions and thereby counteract the progression of the disease. Consequently, other mechanisms than antioxidant protection only are involved in the anti-atherogenic effect of CoQ.
Endothelial function
One of the characteristic events in many diseases, such as diabetes and cardiovascular diseases, is endothelial dysfunction of the arteries which has serious consequences [91] . When the function of the brachial artery was measured as flow-mediated dilatation and glyceryl-trinitrate-mediated dilatation following dietary supplementation with CoQ10, a sizeable improvement of endothelial function was observed [92] . CoQ10 administration to type 2 diabetic patients also lowers systolic blood pressure and HbA 1c but it does not decrease F2-isoprostanes [93] . Increased endothelial release of nitric oxide is the most probable explanation for the arterial effect causing dilatation.
Distribution

Tissues
CoQ is present in all tissues and cells but, on weight basis, in variable amounts (Table 3A) . The lipid is also found in all isolated lipoprotein fractions of human blood [94] . The main species in rat is CoQ9 that varies from 17 Ag/g tissue in lung to 202 Ag/g in heart [52] . About 10-20% of the total CoQ in rat has 10 isoprenes, CoQ10, with the exception of brain, spleen and intestines where 30 -40% of the total is CoQ10. In human the main species is CoQ10 which ranges from 8 Ag/g in lung to 114 Ag/g in heart. Small amounts, 2-7% of CoQ9, are also found in all human tissues. By employing rapid extraction, partition and direct injection of the extract into HPLC, it is possible to estimate the degree of reduction, most probably existing also in vivo [95, 302] . This shows that the degree of the reduced state is very high, more in human than in rat, with the exception of lung and brain. The reducing systems in various organs, as discussed later on, are highly efficient.
The concentration of CoQ varies greatly not only among different organs but also among various cells and regions of the same organ, which is exemplified by the bovine brain in Table 3B [96] . Manifold differences are apparent between the individual regions, indicating both structural and functional specializations, e.g. histological structure and number of mitochondria.
Intracellular distribution
All organelles isolated upon subfractionation of the liver contain the different types of mevalonate pathway lipids, although in most variable amounts ( Table 4 ). The highest amounts of CoQ (on protein basis) are found in the outer and inner mitochondrial membranes, lysosomes and Golgi vesicles. Dolichol is enriched in lysosomes and Golgi vesicles while cholesterol shows the characteristic gradient: rough microsomes!smooth microsomes!lysosomes!Golgi vesicles!plasma membranes. Golgi vesicles are the far most dominant organelle concerning a-T enrichment.
In most species, one chain length of CoQ is dominating and in a minor extent a lipid with a shorter or a longer side chain is also found. The situation is, however, quite different The values are given in Ag/g tissue. Data taken from Å berg et al. [52] and Runquist et al. [96] .
from that of dolichol which is distributed in tissues as a family of polyisoprenoids with six to seven members [97] . It was proposed that the heterogeneity of CoQ is required for functional specializations, such as for mitochondrial respiration and for antioxidative action [98] . The experiences are, however, not in favor of such specialization. In rat brain where one-third of the CoQ has 10 isoprene residues, the distribution pattern is identical in various regions and also in subcellular organelles [99] . The effectiveness to serve as respiratory chain redox carrier or as an antioxidant agent is not influenced by the length of the isoprenoid side chain [100] [101] [102] . Upon reconstitution of extracted beef heart submitochondrial particles, either with CoQ9 or CoQ10 within the physiological range of lipid concentrations, no differences could be observed in the rate of superoxide generation [103] . In spite of these facts, in some cases the type of CoQ species is of importance. Activation of UCPs and regulation of the mitochondrial PTP have selective requirements [71, 78] . It was observed that mumps virus infection of dorsal ganglion cells, which contain both CoQ9 and CoQ10, led to a decrease of these lipids and resulted in neuronal degeneration [104] . The cells could be rescued by addition of CoQ10 to the culture but not by addition of CoQ9.
Intramembranous localization
Lipids of the mevalonate pathway have distinct intramembranous localizations that has considerable consequences on membrane properties. Polyisoprenoid chains of CoQ, dolichol and dolichyl-P are present in the central hydrophobic region, between the double layers of phospholipid fatty acids (Fig. 4) [105 -108] . They probably have a coiled formation and the three lipids saturate the available space, since membrane thickness is considered to be a characteristic of the membrane type investigated. The functionally active groups, the benzoquinone ring of CoQ and the phosphorylated a-isoprene of dolichol-P, turn out to the outer or inner surface of the membrane depending on the functional requirement. This central localization is considered to destabilize membranes and results in an increased fluidity and permeability. On the contrary, the other obligatory membrane component, cholesterol, is distributed between fatty acids on one side of the lipid leaflet, thereby causing stabilization with decreased fluidity and permeability [109] .
This arrangement of isoprenoid-derived lipids has two major consequences. First, all membranes have to be saturated with the appropriate lipid for optimal function and the level of saturation is dependent on the structural organization of the membrane type. Second, if a membrane is deficient in an isoprenoid, the consequences for membrane function, e.g. fluidity, will be deleterious. In this case, one can expect an uptake from exogenous sources up to the limit of saturation. If the uptake continues, the excess lipid has to have a non-membranous distribution. In fact, lysosomes have a CoQ and dolichol content that exceeds several-fold the content of other membranes. After sonication, however, the major part of the lipid content is solubilized, including 80% of CoQ, and the lysosomal membranes exhibit a similar concentration of polyisoprenoids as the other cellular membranes [110] . Also, exogenous CoQ, taken up by the liver and appearing in organelles, can to a large extent be removed by mechanical treatment [111] .
Removal of CoQ from membranes
There are limited possibilities to obtain an in vitro system with different CoQ contents and amounts of other neutral lipids. Extraction with selected organic solvents, preferentially with n-pentane, is one of the few ways for such studies [4] . The principle of this procedure is that membranes prepared in sucrose-free medium are lyophilized and repeatedly extracted with n-pentane. Thereafter, the extracted samples are equilibrated with n-pentane containing various amounts of CoQ (and/or cholesterol, dolichol and a-T). After drying the resuspended fraction, the preparation can be used for various measurements. The great advantage for using this procedure is that only neutral lipids but not phospholipids or proteins are extracted and most of the integral membrane enzymes are not denatured, and one can analyze enzyme and membrane properties in the presence of different CoQ content alone or together with other neutral lipids [112, 113] .
Biosynthesis
The biosynthesis of CoQ has been extensively investigated in bacteria and yeast but only studied to a limited extent in mammals. The terminal part of the bacterial CoQ biosynthesis differs from yeast in the order of synthetic events, i.e. in prokaryotes the modifications of the ring after attachment of the side chain proceeds via a decarboxylation prior to hydroxylation and methylation whereas in eukaryotes decarboxylation occurs after hydroxylation and methylation. All COQ genes isolated from yeast (COQ1-8) have a putative mitochondrial targeting signal and no isoenzymes have been identified [114] . However, CoQ is found in all subcellular compartments and, hence, a transport should exist from mitochondria to other membranes. In mammalian tissues, only two genes (COQ3 and COQ7) have been isolated through complementary recognition with yeast [115, 116] .
The mevalonate pathway
The mevalonate pathway comprises the reactions starting from acetyl-coenzyme A (acetyl-CoA) and ending up with farnesyl pyrophosphate (FPP), the substrate for the biosynthesis of CoQ, cholesterol, dolichol and isoprenylated proteins ( Fig. 5 ) [117] . Thus, the conversion of acetyl-CoA to FPP is common for all end-products. This organization is unusual since the biosynthetic sequence is identical for several lipids and one could expect that production of one lipid greatly influences the synthesis of the other lipids. However, the mevalonate pathway lipids are synthesized in highly different rates and amounts, which involves, in addition to the central regulation, a terminal regulation. The regulatory enzymes are probably the branch-point enzymes utilizing FPP. This fact makes the mevalonate pathway very complex in animal cells.
The initial part of the mevalonate pathway involves the condensation of three acetyl-CoA to 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), which is mediated by two enzymes, acetoacetyl-CoA thiolase and HMG-CoA synthase. HMG-CoA reductase then converts HMG-CoA to mevalonate. This enzyme has been studied extensively and is considered to be the main regulatory enzyme in cholesterol biosynthesis [118] . Effective competitive inhibitors of this enzyme, compactin and mevinolin and their derivatives, are in the western world among the most commonly used drugs [119] . Interestingly, these inhibitors induce the synthesis of the reductase at the transcriptional level and, additionally, inhibit the degradation of the enzyme [120] . The action of inhibitors therefore leads to low enzyme activity but high amount of enzyme. Cholesterol mainly affects HMG-CoA reductase by feedback regulation but the enzyme is influenced by many other mechanisms, e.g., diurnal rhythm, hormones and oxysterols [121, 122] . One of the factors behind the rapid and reversible regulation of this enzyme can be inactivation -activation elicited by phosphorylation -dephosphorylation of the protein [123] .
Mevalonate is subsequently phosphorylated in two steps by mevalonate kinase and phosphomevalonate kinase. Mevalonate phosphates appear, in addition to intermediates, to be regulators of cell proliferation and DNA synthesis [124] . Decarboxylation of mevalonate pyrophosphate yields isopentenyl pyrophosphate (IPP), which is not only a precursor of FPP but also the main building block in the polyisoprenoid biosynthesis of dolichol and the side chain of CoQ. Isomerization of IPP gives dimethylallyl pyrophosphate which is an intermediate in the biosynthetic process of isoprenoid lipids and, furthermore, also participates in the synthesis of isopentenyl tRNA ser/sec at the position six of an adenosine (i 6 A) [125, 126] . This isoprenylation of tRNA ser/ sec is necessary for an effective selenoprotein synthesis. Farnesyl pyrophosphate synthase utilizes IPP and its isomer dimethylallyl pyrophophate to make FPP with the formation of an intermediary product, geranyl pyrophosphate (GPP) [127] . This model involves GPP's presence only as an enzyme-bound intermediate. On the other hand, it was previously found that GPP-at least in in vitro conditions-is serving as the main precursor in solanesyl pyrophosphate and decaprenyl pyrophosphate synthesis both in rat liver and spinach homogenates [128, 129] . If the major substrate for trans-prenyltransferase is GPP also in vivo, it should be a GPP pool for this purpose. Direct measurements of possible pools concerning mevalonate, FPP and GPP are, however, not yet made and therefore this question is unanswered. During various experimental conditions like fasting, cholesterol feeding, treatment with cholestyramine or mevinolin, FPP synthase is influenced in coordination with HMG-CoA synthase and HMG-CoA reductase activities [130] . The major part of hepatic FPP synthase is present in the cytoplasm but some activity is found in all organelles isolated [117] . The enzymatic activity at different locations exhibits different responses upon treatment of rats with inducers and drugs, which demonstrate that the enzyme is subjected to separate regulation depending on its location in cytosol, microsomes, mitochondria or peroxisomes [131] .
The next enzymes in the biosynthesis of cholesterol, dolichol, CoQ and protein isoprenylation, i.e. squalene synthase, cis-prenyltransferase, trans-prenyltransferase and farnesyl-protein transferase, are considered to be the ratelimiting enzymes in the terminal part of their biosynthetic process. The isoprenoid biosynthetic enzymes in the mevalonate pathway are evolutionarily closely related. X-ray 
The terminal part of CoQ biosynthesis
Although the genes in the terminal part of the CoQ biosynthesis have been cloned in bacteria and to some extent in yeast, there is still a limited amount of information about the biosynthetic enzymes in mammalian tissues. The genes so far identified as encoding the enzymes in CoQ synthesis are given in Table 5 .
trans-Prenyltransferase, Coq1p
The trans-prenyltransferase catalyzes the condensation of FPP with several IPPs, all in trans configuration, to form a long isoprenoid chain. The enzyme belongs to class III enzymes in the trans-prenyltransferase family. While class I enzymes produce short isoprenoid chains and class II produces medium and long chains, class III only produces long isoprenoid chains. Although the short chain enzymes (e.g. FPP synthase) have been thoroughly characterized, the class III enzymes are still elusive. Only a few enzymes have been isolated, all in bacteria and yeast, and their characterization is based on complementary rescue of null mutants [133] . Most of them form homodimers and all require Mg 2+ for activity. All classes share several conserved aspartic acid-rich sequence motifs and the length of the side-chain produced is species-specific. For instance, Saccharomyces cerevisiae make CoQ6, E. coli synthesizes CoQ8 and rodents and humans produce mainly CoQ9 and CoQ10, respectively. This specificity is retained within the gene sequence, since cross-expression of genes has shown that the length of the side chain is altered when a different transprenyltransferase encoding gene is expressed [134] . It is believed that Mg 2+ serves to bind the substrate and that the region located around the first aspartic acid-rich motif regulates the length of the side chain produced. Especially the fifth amino acid, upstream the first aspartic acid-rich motif, seems to be important. If this amino acid is changed from alanine to an aromatic amino acid, the polyisoprenoid produced is shifted from a long chain to geranylgeranyl pyrophosphate [132] . The reverse has also been shown using FPP synthase and geranylgeranyl pyrophosphate synthase [135, 136] .
While the yeast trans-prenyltransferase is considered to be a mitochondrial protein, mammalian trans-prenyltransferase activity is mostly found in the ER, while lower activities are found in the mitochondria, Golgi vesicles and peroxisomes [128] . The rat trans-prenyltransferase also has a requirement for divalent cations but prefers trans-GPP and IPP as substrates. In vitro measurements of the rat and mouse trans-prenyltransferase have shown that the activity can be induced by administration of peroxisomal inducers [128, 137] .
Polyprenyl-4-hydroxybenzoate transferase, Coq2p
In the terminal part of CoQ synthesis two substrates are required, polyprenyl pyrophosphate and the ring structure, 4-hydroxybenzoate (Fig. 6 ). This latter substrate originates from tyrosine but theoretically it may also be deduced from phenylalanine either by hydroxylation to tyrosine or by enzymatic transformation similar to that of the tyrosine molecule. The intermediates given in Fig. 5 are produced by the action of transaminase, dehydrogenase, dehydratase and completed by a h-oxidation. It was found that this h- oxidation is KCN-insensitive which is diagnostic for the peroxisomal oxidation, but the localization of biosynthesis is not analyzed in detail [138] . Since tyrosine is an essential amino acid in animal cells, contrary to bacteria and yeast, availability of the ring could be rate-limiting in an in vivo system. The experience is, however, that this substrate is in excess in tissues and the fact that 4-hydroxybenzoate is in 10-fold excess in the urine compared to the daily need for CoQ biosynthesis also supports this assumption [139] . Since 4-hydroxybenzoate is a common bacterial product in the intestinal system of animal organisms, it is possible that this supply is far exceeding that of endogenous production. The second step in the terminal part of CoQ biosynthesis is the condensation of the polyisoprenoid side-chain with 4-hydroxybenzoate (Figs. 5 and 6 ). The gene encoding polyprenyl-4-hydroxybenzoate transferase (COQ2) is cloned and characterized in yeast and E. coli (UBIA), but the mammalian COQ2 homologue has not yet been identified. The predicted amino acid sequence of the yeast and E. coli gene exhibits two conserved aspartic rich motifs, which are believed to bind polyprenyl pyrophosphate [140, 141] . The yeast COQ2 contains a typical Nterminal mitochondrial leader sequence but the microsomal enzyme activity is nearly as high as the mitochondrial activity and both of these activities are absent in the coq2 mutant [140] . The UBIA gene has been overexpressed and characterized in E. coli, giving a 3000-fold enrichment in activity [141] . The enzyme was not solubilized by hypertonic buffer or detergent and was shown to be Mg 2+ -dependent. A broad spectrum of isoprenoids (GPP, FPP and solanesyl-PP) was accepted as substrates by this enzyme. The transferase can be inhibited in vitro by benzoate ring analogues such as 4-aminobenzoate and 4-chlorobenzoate, however, these inhibitors are not operating in vivo [142] . In cell culture, 4-aminobenzoate is competing for solanesyl-PP and is condensated with the polyprenol while no direct interaction is occurring with 4-chlorobenzoate. It appears that -SH groups are essential for the transferase activity since 4-hydroxymercuribenzoate is inhibitory. In vitro activity of the rat enzyme is found in the Golgi vesicles, but also in the ER, mitochondria and peroxisomes [112,137,143 -145,177] . The enzymatic activity can be up-regulated by administration of the peroxisomal inducer clofibrate [137] .
There are alternative possibilities to 4-hydroxybenzoate as acceptor of the polyisoprenoid side chain (Fig. 7) . One of the proposals is that like fatty acids, the ring has to be activated with coenzyme A in order to interact with the side chain [146] . Modifications of the ring which are considered as subsequent reactions (hydroxylation and methylation) may precede the condensation reaction [138, 144] . An interesting possibility is that products of the catecholamine metabolism, protocatechuic and vanillic acid, which are substituted derivatives of the 4-hydroxybenzoate, are qualified for completion to CoQ.
2,3-Dihydroxy-5-polyprenylbenzoate-methyltransferase, Coq3p
There are two O-methylations in the production of CoQ and the same enzyme presumably catalyzes both (Fig. 6 ). In eukaryotes, the first O-methylation occurs after polyprenyl-4-hydroxybenzoate has been hydroxylated. However, it has been suggested by Kang et al. [147] that the decarboxylation actually occurs before the first hydroxylation and methylation in rodents. The enzyme was first partially purified and characterized in yeast and it was concluded that S-adenosylmethionine (SAM) was the methyl donor [138] . Tzagoloff and Dieckmann isolated nine separate complementation groups in yeast containing reduced levels of CoQ, which led to the identification of COQ3 in yeast and UBIG in E. coli [148 -150] . The predicted amino acid sequence for the proteins of COQ3 and UBIG contains four sequence motifs that are conserved in a large family of enzymes utilizing SAM as methyl donor [151, 152] . The rat COQ3 cDNA was recovered by its ability to rescue CoQ biosynthesis in yeast coq3 mutants [153] . Its N-terminus shares the features common for mitochondrial import sequences. The rat cDNA has then been used to map the mouse COQ3 to the proximal region of chromosome 4 and for the identification of the fulllength human cDNA [115, 154] . Using farnesylated analogues, 2,3-dihydroxy-5-polyprenyl-1,4-benzoic acid and demethylubiquinone, together with radiolabeled SAM, it was concluded that the same enzyme could possibly perform both O-methylations and that Coq3p or UbiGp is required for in vitro activity in yeast and E. coli [155, 156] . The activity of Coq3p was found in yeast mitochondria and cell-free extracts of E. coli. Using [
3 H]SAM, we have also found an in vitro methylation activity of the farnesylated analogues (supplied by C.F. Clarke, UCLA) in rat liver microsomes and mitochondria. However, the major part of the activity was recovered from the cytosol and therefore it is unclear to what extent the cytosolic catechol-O-methyltransferase contributes to these activities. Catechol-O-methyltransferase shares several features with the Coq3p, since they are both dependent on a divalent cation and utilize SAM. Their amino acid sequences, however, fail to show any homology with yeast COQ3 outside the sequence motifs for SAM binding that are conserved for all SAM-dependent enzymes.
3-Methoxy-6-methyl-5-polyprenyl-benzoquinone-hydroxylase, Coq7p
The second out of two mammalian genes identified in the terminal part of the CoQ biosynthesis is COQ7 [116] . The enzyme hydroxylates 3-methoxy-6-methyl-5-polyprenylbenzoquinone (demethoxy-ubiquinone) yielding 2-hydroxyubiquinone [157] . The yeast gene was independently isolated as CAT5, and was thought to be encoding a protein required for release of gluconeogenic genes from glucose repression [158] . Later studies, however, showed that this gene is directly involved in CoQ biosynthesis and that the defect in gluconeogenetic gene activation could be restored by CoQ supplementation [159] . CoQ biosynthesis in S. cerevisiae coq7 null mutants could be restored with the complementary COQ7 genes from rat, humans or the CLK-1 gene from C. elegans [116, 160, 161] . The clk-1 mutants show early developmental arrest and sterility, and this phenotype can be rescued by a dietary source of CoQ [162] . The mouse clk-1 mutant accumulates demethoxyubiquinone in heart and liver mitochondria. This product is redox active and can partially compensate for some of the defective respiratory functions seen in C. elegans clk-1 mutants [163] . It appears, however, to lack capacity as antioxidant. The CLK-1 is a gene determining the life span and was found to be conserved among eukaryotes, such as yeast, rodents and humans [161, 164] . Consequently, the interest for this gene is accentuated and the fact that the CLK-1 homologue COQ7 is participating in CoQ biosynthesis gives great possibilities for hypotheses concerning connections between life span and CoQ metabolism.
In a recent study using RNA inteference, eight genes of CoQ synthesis (COQ1 -8) were identified in C. elegans [184] . It was demonstrated that not only CLK-1 but all the other genes are of importance for life span in C. elegans. In silencing experiments of the individual genes, there were unchanged mitochondrial respiratory activities but superoxide production was decreased and life span were extended.
Other CoQ biosynthetic enzymes
There are eight modifications of the benzoate ring and only two mammalian genes are isolated and their enzymes partly characterized [115, 116] . Coq3p catalyzes two Omethylations and coq7p catalyzes one hydroxylation. Out of the remaining five reactions (C-methylation, decarboxylation and three hydroxylations) only some have been characterized in yeast and bacteria. The COQ5 gene has been attributed to the C-methylation of the ring and the COQ6 gene is suggested to be involved in one of the hydroxylations [165, 311] . COQ4 and ABC1/COQ8 have been isolated although their function is unknown [114, 166] . The UBIB gene of E. coli was recently identified and proposed to be involved in the first monooxygenase step [167] . Although the genes are now identified, much of the work on the biosynthesis of CoQ is still inconclusive and further work on a protein level is needed before the COQ genes can truly be attributed to the individual steps in CoQ biosynthesis. Identification and characterization of the individual steps, however, may turn out to be more difficult than it appears at present. The studies of Hsu et al. [168] have established that the major sequence of CoQ synthesizing enzymes, products of COQ3-COQ8, is organized in a multi-subunit complex in yeast. Consequently, the individual coq null mutants do not necessarily produce the appropriate intermediate which can be used both for identification and as substrates in enzymatic studies, since the presence of all polypeptides may be required for the proper function and stability of the complex. In fact, the different yeast coq mutants (coq3 -coq8) fail to produce CoQ and all of them accumulate mainly or exclusively 3-hexaprenyl-4-hydroxybenzoic acid. This compound is the product of the protein controlled by the COQ2 gene, which parallels the Coq1p by not participating in the complex. It appears probable that in animal tissues the organization of the biosynthetic system is similar, since both isolated perfused beating rat heart and mitochondria prepared from rat heart accumulate nonaprenyl-and decaprenyl-4-hydroxybenzoate [169, 170] .
Intracellular transport
Independently of the locations of CoQ synthesis, the lipid has to be transported within the cell since all cellular membranes contain CoQ. In animal cells the mitochondrial inner membrane, but not necessarily the outer membrane, probably receives all of its CoQ from the synthetic machinery located in the matrix -inner membrane space [138] . Liver perfusion studies established that VLDL assembled in the ER -Golgi system contain newly synthesized CoQ [171] . It is known that all components of the lipoprotein have to be synthesized at the location of the assembly. Newly synthesized CoQ is part of the lipoprotein, necessary for antioxidant protection. The way of transport of the lipid from the ER -Golgi system to other cellular compartments is not established. For lipid transport in general, three mechanisms are described: vesicular transport, carrier protein-bound transport and transport involving micellar formation, all of which are possible transport ways also for CoQ [172] . Using in vivo labeling and cell fractionation, it was found that in spinach leaves CoQ is transported from the ER to other compartments through a vesicle-mediated process, which involves the Golgi system [173] . Monensin and brefeldin are perturbing the Golgi system, resulting in an accumulation of the lipid in the ER. In this system the transport of CoQ is ATP-dependent but the cytoskeletal network is not involved. Similar conclusions were attained by applying a reconstituted cell-free system using mem-brane fractions isolated from dark-grown spinach seedlings [174] .
Transport also occurs in the opposite direction since exogenous CoQ is translocated through the plasma membrane and further intracellular transport again requires an appropriate mechanism. After administration of exogenous [ 3 H]CoQ to rats, followed by subcellular fractionation, the lipid was recovered from transport vesicles found in the fatty layer and from possible carrier proteins in the cytosol [111] . Recently, a new system was described which may be of great help in studying the transport mechanism. CoQ is absent in the electron transport chain of some yeast mutants which, however, are able to take up external CoQ into the plasma membrane and subsequently transport it into mitochondria [175] . In this way it is possible to reconstitute the deficient electron transport chain. In some other mutant strains the exogenous CoQ remains in the plasma membrane since there is a defect in the transport mechanism and the lipid is not delivered to mitochondria. Using this approach, yeast mutants may be useful for detection and characterization of specific transport vesicles in the cytoplasm as this mechanism probably is involved in the translocation process in other species.
Compartmentalization of the mevalonate pathway
It is common that a single biological process or enzymatic sequence has several locations in the animal cell contrary to one-cell organisms where functions are often concentrated to a single membrane system. The mevalonate pathway in rat liver is a good example for the complexity of cellular organization (Fig. 8) . Acetyl-CoA is the initial substrate for the product which is FPP. The major part of enzymes mediating the reactions of the pathway is present in the cytoplasm with the exception of HMG-CoA reductase which is located in microsomes and peroxisomes. However, FPP synthase is present also at other compartments than in the cytosol. Both mitochondria and peroxisomes can utilize IPP for FPP synthesis, which means that both organelles contain the isomerase and FPP synthase. Since several enzymes of the mevalonate pathway are found in peroxisomes, it is also possible that peroxisomes contain the complete pathway in spite of the fact that earlier substrates than IPP cannot be used for FPP synthesis under in vitro conditions. Microsomal synthesis of the isoprenoid sidechain of CoQ requires GPP rather than FPP as substrate in both plants and rat liver, which is not explained so far, since FPP synthase mediates a two-step reaction from dimethylallyl pyrophophate and GPP is supposed to be present only as an enzyme-bound intermediate. It is possible that some of the terminal reactions distributed in various subcellular organelles of rat liver require FPP to be synthesized in the organelles themselves in order to be utilized by the branchpoint enzymes of the same organelle. An alternative possibility is that a part of the synthase has structural association with the appropriate membrane by hydrophobic or charge forces and FPP is directly channeled into the membrane without releasing the product, to serve FPP requiring reactions.
CoQ biosynthesis is studied in mitochondria and in the ER -Golgi system of both liver and spinach leaf [129, 138, 145, 176] . Recently, trans-prenyltransferase and nonaprenyl-4-hydroxybenzoate transferase were also found in peroxisomes [177] and continued studies are required to establish the presence of other CoQ biosynthetic enzymes in this organelle. The presence of CoQ synthesis at several locations in animal tissues is not surprising, since other mevalonate end products are also produced at several locations. Cholesterol and dolichol are synthesized in both microsomes and peroxisomes, while protein isoprenylation takes place in mitochondria and microsomes, in addition to cytosol [178 -180] .
In general, the synthesis in two organelles does not mean a simple doubling of the reactions but is rather related to a specialization. h-Oxidation of fatty acids in mitochondria and peroxisomes are utilizing different substrates and the two organelles are cooperating in the total oxidation [181] . Mitochondria are probably producing CoQ for the respiratory chain and for other mitochondrial functions. On the other hand, mitochondria cannot deliver CoQ for blood lipoproteins and newly synthesized VLDL, during the transport from the ER -Golgi system to the blood, has to acquire this lipid from local synthesis. Also, ER -Golgi CoQ is the most reasonable source of this lipid in other cellular membranes, including plasma membranes, since transport mechanisms from this system to other membrane compartments are well established.
CoQ is present in various amounts in different cellular organelles, reflecting a compartmentalization. In fact, the function of this lipid in mitochondria, plasma membrane and in microsomes is certainly different. Another type of specific distribution is that of lysosomes, i.e. the presence of the lipid in both the membrane and the vesicle lumen [110] . This luminal CoQ is not necessarily a storage compartment, it may exert functional effects. The possibility that the lipid is compartmentalized also within the membrane is raised repeatedly [182, 183] . In the mitochondrial inner membrane CoQ has at least four different functions, redox carrier, activating UCPs, PTP regulation and antioxidant, which makes it improbable that only one common pool is operating (Fig. 9) . UCP requires an association with oxidized CoQ10 for activation which hardly allows this pool to cooperate with either those portions participating in the respiratory chain or with those acting as antioxidant [70] . The fact that the decrease of the CoQ content by 60 -70% in C. elegans does not effect CoQ-dependent mitochondrial electron transport is also supporting the concept of compartmentalization [184] . It would be of great interest to study also other CoQ-dependent mitochondrial functions in this system.
Regulation of the mevalonate pathway
The main regulatory enzyme of the mevalonate pathway is HMG-CoA reductase, preferentially affecting cholesterol synthesis. This is according to the classical flow diversion hypothesis, in which the size of the FPP pool mainly influences cholesterol synthesis [185] . Squalene synthase has a high K m for its substrate, FPP, and already a limited decrease in concentration leads to insufficient saturation of the enzyme and thereby reduction of cholesterol synthesis. Since the K m for the other branch point enzymes, cis-and trans-prenyltransferases and farnesyl-protein transferase, are lower, these enzymes are saturated even at lower substrate concentrations. This kinetic arrangement is the basis for the use of our most common drug, statins, inhibitors of the HMG-CoA reductase. However, we do not know the actual K m for the various enzymes, with the exception of farnesylprotein transferase [186] , since not all of them are isolated and no values are available for direct comparison. Most probably, the differences in K m are not as great as it is assumed. Statin treatment, both in rats and humans, appears to affect the amount and synthesis of all mevalonate pathway lipids [128,187 -191] . CoQ amounts are decreased in heart, muscle and liver after mevinolin treatment of rats, indicating the importance of a decreased FPP pool on the trans-prenyltransferase reaction [192] . Inhibition of squalene synthase by squalestatin-1, which increases the FPP pool, elevates CoQ synthesis both in tissue culture cells and in rats in vivo [193, 194] .
Metabolites and intermediates function commonly as regulatory substances for metabolic pathways, but none is described so far for CoQ biosynthesis. A good candidate for such a role is farnesol or one of its metabolites, e.g., farnesyl esters, hydroxyfarnesol, farnesoic acid or dicarboxylic acids. Farnesol is suggested to be involved in cell growth, phosphatidylcholine synthesis, ROS generation, apoptosis, HMG-CoA reductase degradation, regulation of protein kinase C and Ca 2+ channels, and additional functions will most probably appear in the future [195 -197] . There are also other candidates for a regulatory function in CoQ biosynthesis. These are the biosynthetic intermediates or their modified forms such as the partially substituted ring structure without side chain, like vanillic acid. Metabolites are also produced upon ultraviolet irradiation and after lipid peroxidation in membranes, if the CoQ is present in oxidized form [60, 198] . Some of these products may be of considerable interest in future studies.
Hormones are the well-established regulators of a large number of tissue functions and CoQ is not an exception from this rule. Very few studies are made in this field but it is known that growth hormone, thyroxine, cortisone, adrenaline and dehydroepiandrosterone treatments increase the CoQ amount in rat liver [199] . Administration of thiouracil, inhibitor of thyroid hormone production, decreases the lipid concentration in liver [200] . Exposure of rodents to cold temperature at 4jC increases liver CoQ [201] . It remains to be investigated whether this increase is under hormonal control.
Rats which receive protein-free diet exhibit a decreased CoQ content in liver and heart but not in kidney, spleen and brain [202] . From the experimental point of view, the problem is naturally that these changes are not selective but affecting a number of other biosynthetic systems and, consequently, it may be difficult to relate functional modifications to CoQ deficiency.
Endurance exercise training increases CoQ concentration in rat muscle on weight basis [203, 204] . It appears that this elevation is mainly explained by the increase of the mitochondrial mass. In human, 4 days of high intensity training does not elevate CoQ content in the exposed muscles [205] . Dietary CoQ10 appears in the plasma but not in the skeletal muscle or in mitochondria isolated from the muscle of the control or training group.
Contrary to the situation with cholesterol, dietary and diurnal variations do not appear to modify the tissue CoQ content. Dietary vitamin A deficiency increases while vitamin A administration decreases CoQ amount in liver [200, 206] . Selenium deficiency in rat decreases CoQ content in the liver by 50%, and some decrease also occurs in heart and kidney but not in muscle [207] . Interestingly, the decrease in liver does not affect plasma membranes which exhibit an elevated CoQ content [208] . a-T and CoQ levels in blood and tissues appear to be modified in a parallel fashion which is probably expected because of the close functional relationships between these two lipids. Upon dietary administration of vitamin E, not only the vitamin itself but also CoQ is increased in blood and liver [209] . On the other hand, vitamin E-deficient diet decreases the concentration of both lipids. When these lipids are supplied together in the diet, the efficiency of the uptake is increased in liver and spleen but no uptake was observed in heart, kidney, muscle and brain [210] . On the other hand, higher amount of CoQ was found in mouse heart, skeletal muscle, kidney, brain and liver upon CoQ administration and the uptake of CoQ was lowered when not only this lipid but also a-T was included in the diet [211] . The differences seen in these studies could be due to the method of administration, composition of basal diet and the strain used. In hyperlipidemic patients not only blood triglycerides but also both CoQ and a-T are increased [212] . When these patients were treated with gemfibrozil, blood lipids were normalized and a parallel decrease of both CoQ and a-T was observed. CoQ diet in humans increases not only this administered lipid in monocytes but also that of a-T [88] . In prion diseases of mice both lipids are greatly increased in the brain [213] . The close relationship in the parallel modifications of the two antioxidant lipids is probably a biological necessity. CoQ can regenerate a-T in vitro and thereby protect it from being decomposed by a second radical attack, and it is therefore reasonable that these two antioxidants act in concert [214] .
Enzymatic reduction of CoQ
For the antioxidant function of reduced CoQ, it is of great importance that the reduced form can be regenerated at all cellular locations [303, 304] . Several investigators have so far studied the regeneration of CoQ and different CoQ reductases have been suggested as reduction enzymes. It was proposed that there is a cytosolic NADPH-dependent CoQ reductase which is different from the mitochondrial NADH-CoQ reductase and DT diaphorase as it is rotenoneand dicumarol-resistant [215, 216] . The most studied enzyme so far is DT-diaphorase, a cytosolic homodimeric enzyme [217, 218] . This enzyme has been shown to possess the capacity to reduce CoQ but it is less efficient for longer isoprenoid side chain length, i.e. those with 9 or 10 isoprene units [219] .
Recently, it has been shown in vitro that the enzymes lipoamide dehydrogenase, thioredoxin reductase and glutathione reductase efficiently could reduce coenzyme Q10 [220 -222] (Nordman, T. Björnstedt, M. Olsson, J.M., unpublished data). These FAD-containing enzymes are homodimeric with subunits that have a molecular weight of about 55 kDa and belong to a family of pyridine nucleotide disulfide oxidoreductases [223 -225] . Lipoamide dehydrogenase is mainly known to participate in the three a-ketoacid complexes located in the inner mitochondrial membrane [226] , however, this enzyme and the other two oxidoreductases are present also in the extra-mitochondrial space. All three enzymes can reduce lipoic acid to its antioxidant form dihydrolipoic acid. In turn, dihydrolipoic acid was demonstrated to be able to reduce CoQ [227] . Although thioredoxin reductase belongs to the same family as lipoamide dehydrogenase, there are crucial structural differences affecting the functions of this enzyme. The Cterminal part of thioredoxin reductase is in comparison with lipoamide dehydrogenase elongated with about 20 amino acids that contain a cysteine and a selenocysteine adjacent to each other [228] . The incorporation of selenium as selenocysteine has been suggested to be facilitated by isopentenylation of the tRNA ser/sec via the mevalonate pathway (see above) [125] . The exceptionally broad substrate specificity is probably connected with this selenenylsulfide as it is located close to the active disulfide site, consisting of the conserved sequence Cys-Val-Asn-Val-Gly-Cys, at the Nterminal of the other subunit [228] . It is obvious that these enzyme systems are connected and contribute to an elevated level of resistance against oxidative stress in the cell.
Dietary uptake
CoQ is taken up from the intestine into the circulation with a low rate, only about 2 -4% can be recovered [229] . The mechanism of uptake is not studied in detail but since it is found in the various lipoproteins, redistribution in the circulation appears to occur. In the case of a-T, the liver possesses a specific binding protein which delivers it back to the circulation via VLDL for further transport to different organs [230] . The limited amount of information available indicates that VLDL synthesized in the ER -Golgi system contains only de novo synthesized CoQ in an amount which is required for antioxidant protection but not for redistribution to tissues [171] . Tritium-labeled dietary CoQ in liver is either metabolized or excreted into the bile and thereafter removed from the body [111] . In liver, spleen, adrenals, ovaries, arterial endothelium, blood monocytes and lymphocytes from rat, CoQ is taken up from the circulation while the uptake by heart, pancreas, pituitary gland, testis and thymus is very limited. No uptake is visible in kidney, muscle, brain, thyroid gland and blood polynuclear cells. Uptake into the brain was observed in an investigation and it cannot be excluded that the particular conditions used in this study influence the results [232] . Species difference is probably a deciding factor as in mice dietary CoQ appear in various organs [231] .
We have tried to improve the uptake of CoQ by administering two synthesized derivatives, disuccinylated (SQ) and diacetylated CoQ (AQ) [233] . This method of administration has been described for a-T earlier [234] . The objective was to maximize the plasma concentration of CoQ and hence induce CoQ uptake into tissues. The plasma levels of CoQ were indeed increased when SQ or AQ were administered in comparison with non-derivatized CoQ. However, none of the treatments showed any increase of the lipid uptake into various tissues. Furthermore, SQ and AQ were recovered in the plasma, liver and spleen as underivatized CoQ, indicating the presence of highly effective esterases in the circulation and the intestine.
The uptake mechanism of CoQ from the blood into tissues is not yet studied. Like cholesterol and a-T, LDLreceptor may be one of the mediators since organs such as adrenals and ovaries are rich in this receptor. This mechanism of uptake is probably not the only one since in some organs the receptor level and the degree of uptake are different. Another possibility is that a CoQ-specific receptor or binding protein is operating.
The limited uptake of external CoQ by animal tissues is explained by its distribution, cellular location and functional requirements. The localization of the lipid in the central hydrophobic portion make membranes saturated and there is no functional requirement or possibility to place more lipids into the limited space. Since all type of cells have the CoQ biosynthetic pathway, no external lipid is required under normal conditions [235] . In fact, labeled CoQ taken up by the liver does not appear in the mitochondria where more than 80% of the endogenous lipid is found [111] . It is distributed mainly in non-membranous luminal compartments, preferentially in lysosomes [110] . The situation is however different when the lipid is missing and the membrane has the capacity, at least theoretically, to accept the lipid. This situation is well documented in children with genetic deficiency of CoQ synthesis [236] . These cases, where there is almost complete lack of the lipid in fibroblasts and lymphoblasts, are associated with severe neuronal and muscular symptoms. Dietary CoQ improves dramatically the physical and intellectual capacities by restoring deficient mitochondrial respiration. Another case is patients with cardiomyopathy who exhibit low levels of CoQ in heart biopsy samples [237 -239] . After CoQ supplementation, the uptake is higher in severe heart disease in comparison with the uptake in mild disease. Consequently, uptake and proper tissue and cellular distribution of external CoQ take place also in animal and humans, presupposing that there is a requirement. If this is not the case, CoQ is either not taken up, or it appears in cells mainly in the lumen of some organelles. It is, however, possible that this nonmembranous lipid is functionally active. It is not clear how CoQ deficiency is defined and when a decrease in amount affects a function. In 1-year-old rats the amount of CoQ is decreased in most tissues but the uptake into organs upon dietary administration is not higher than in young rats [233] .
Administration of an exogenous substance may have consequences for the production of the endogenous product. In vivo labeling of endogenous CoQ with 3 H-mevalonate demonstrated that there is no product inhibition upon dietary administration of the lipid [192] . In some studies, obviously depending on the experimental conditions, an increase in endogenous CoQ9 in rodents was described upon supplementation of CoQ10 [231, 232, 241] . A possible explanation is that the exogenous lipid is metabolized and some of the breakdown products act as stimulatory agents on the biosynthetic mechanism.
The above discussion dealt with the direct organ uptake of CoQ and its consequences. However, one has to keep in mind that direct cellular uptake is not the only possibility for action. The established way of action for many substances does not require entrance into the cell. Signal transduction, redox signaling, acting as primary ligand or secondary transducer are the possibilities for such action by CoQ. Influence on organ circulation and effect on the vascular system are other possibilities since this lipid is taken up to the blood. CoQ in the circulation may effect the production of cytokines and interleukines, change the levels of adhesion molecules and modify the production of prostaglandin and leukotriene metabolites. The presence of this antioxidant in the gastrointestinal system is an efficient way to prevent formation of interactive free radicals. Even small amounts of metabolites originating from CoQ, either from normal catabolism or by other ways (e.g. radiation or oxidation), may have considerable influence on many processes considering the effects of many drugs after metabolism. In this way, it may turn out that in spite of the limited organ uptake, dietary CoQ has an important influence on organ metabolism and function.
Catabolism
CoQ has a high catabolic rate which is indicated by the relatively short half-life, T 1/2 ( Table 6 ). The half-life varies among tissues and it ranges between 49 and 125 h [242] .
The T 1/2 of the mevalonate pathway lipids is similar in most tissues which is, however, not the case in brain [243] . In this organ both cholesterol and dolichol have a very high T 1/2 , 4080 and 1010 h, respectively, while it is 90 h for CoQ. This finding demonstrates the importance of CoQ in the brain and also shows the operation of terminal regulation in the mevalonate pathway. Despite of the same initial reactions leading to FPP, the rates of biosynthesis for the three lipids are completely different. The relatively rapid breakdown of CoQ is not only an event in animal cells but also occurs in plants [244] .
The catabolism of CoQ has been studied only to a limited extent. Breakdown products isolated from urine and feces of rat and guinea pig were characterized using mass spectrometry and it was found that the main products have an intact, fully substituted ring [245, 246] . Using dietary CoQ7 in rat and guinea pig, it has been suggested that the liver degrades CoQ by initial N-oxidation and subsequent h-oxidations of the side chain. The main product identified in the urine had an aromatic ring, the side chain was shortened to 5-7 carbon atoms and the N-end was carboxylated. When [ 3 H]CoQ10 was injected to rats, radioactive water-soluble metabolites could be isolated from all those organs which take up the administered lipid [111] . The metabolites were found mainly in the urine, but also recovered in the feces (discharged through the bile), where even considerable amounts of nonmetabolized [
3 H]CoQ10 were found (Fig. 10) . At HPLC analysis of the urine extracts, two main metabolites were isolated and both of them gave a signal at m/z 389 in mass spectrometry. Upon fragmentation, two signals at m/z 79 and 80 appeared, corresponding to PO 3 (m/ z 79) and HPO 3 (m/z 80). The main metabolite in the urine, isolated by Nakamura et al. [246] , in the phosphorylated form has a calculated molecular weight of 389 which is probably the major breakdown product of CoQ (Fig. 10,  insert) . The two major products isolated on HPLC with identical molecular weight are most probably the same products but phosphorylated either at carbon 4 or alternatively at carbon 1.
By analysis of metabolites in the bile of guinea pig, it was found that conjugation occurred by glucuronidation which derivatives appeared in the feces [246] . In contrast to many other organs, the liver has a high glucuronidation capacity and this type of conjugation obviously takes place also in the liver for CoQ metabolites [247] . Conjugation of breakdown products by phosphorylation is not a common mechanism, but it is necessary in this case since this Data taken from Thelin et al. [242] and Wanke et al. [244] . mechanism has a broad distribution and CoQ catabolism occurs in all tissues. It is also possible that minor products are conjugated by other mechanisms, such as sulfation or glutathione conjugation. Further studies will be necessary to establish the mechanism of the catabolism and identification of enzymes participating in this process.
Both gas chromatography-mass fragmentography and HPLC analyses have demonstrated that the metabolites isolated after injection of labeled CoQ are identical with the metabolites present in the urine produced after endogenous catabolism [111, 246] . CoQ is synthesized in all cells of the animal organism and the lipid is also broken down in all cells. Before the products are discharged to the circulation, they are conjugated by phosphorylation to make them more hydrophilic. These metabolites are transported in the blood to the kidney where they are excreted by the glomerular -tubular system. In liver the main form of conjugation is glucuronidation and the discharge system is the bilefeces route.
Induction of CoQ biosynthesis
Lipid metabolism is regulated in a great extent by peroxisomes and this organelle has a high ability of proliferation. A large number of structurally different natural and synthetic compounds are known as peroxisomal inducers, such as hypolipidemic and anti-inflammatory drugs, some solvents, herbicides, plasticizers, surfactants and food flavors [248, 249] . Increased numbers of peroxisomes are also observed at high-fat diet, vitamin E deficiency, cold adaptation, diabetes and at increased level of dehydroepiandrosterone. Fibrates are commonly used drugs for treatment of hyperlipidemia to decrease mainly blood triglycerides. In humans there is also an induction of some peroxisomal enzymes but no increase in the number of peroxisomes [250] .
When rodents are treated with peroxisomal inducers, CoQ amount increases in various organs [251, 252] . Among the most effective inducers in rat is the plasticizer di(ethylhexyl)phthalate (DEHP), which after 6 weeks of administration in the diet increases CoQ amount in the liver by five times (Fig. 11) . There is also an increase in other organs, such as heart, muscle and blood but not in brain. Other inducers, clofibrate, salicylic acid and dehydroepiandrosterone, also give similar but less pronounced effects. The inducer is species-specific and in mouse the highest induction is obtained by administration of perfluorooctanoic acid [248] . The elevated levels of CoQ are the result of increased synthesis while the breakdown rate is unaffected [240] . In agreement with the enhanced biosynthesis is the finding that in vitro activities of trans-prenyltransferase and nonaprenyl-4-hydroxybenzoate transferase are up-regulated [253] . This is of importance since one of these enzymes is considered to be rate-limiting in the biosynthesis of CoQ. In young rats there is a manifold activation of fatty acid hoxidation in the liver upon DEHP treatment which remains high also in old (17-month-old) animals [240] . Contrarily, the induction of CoQ amount of 42-day-old rats is as high as sevenfold, but in 17-month-old rats the induction of CoQ is completely absent. Consequently, other factors that are also altered during aging control the induction of CoQ biosynthesis by peroxisomal inducers.
Cold exposure of rats elevates the amounts of CoQ in the liver threefold after 3 weeks [201] . In mice the induction is 60% and restricted to the liver [254] . In vivo incorporation of [ 3 H]mevalonate demonstrates that the changes are elicited by an increased biosynthesis of the lipid.
Transcriptional regulation of lipid biosynthesis
Nuclear hormone receptors are ligand-dependent DNA binding transcription factors that exert control on gene expression. They make up a superfamily of more than 150 members that are divided into two groups, the steroid receptor family and the non-steroid receptor family. Nuclear hormone receptors probably arose from preexisting protein modules during evolution and can be linked back structurally to Pex11p, a peroxisomal membrane protein in unicellular eukaryotes [255] . Nuclear receptors share common structure/function domains, i.e. a variable N-terminal region, a conserved DNA binding domain (DBD), a conserved ligand binding domain and a variable C-terminal region [256] . The DBD targets the receptor to specific DNA sequences or response elements and is composed of two highly conserved zinc fingers generated by two cysteinerich motifs. Nuclear receptors form monomers, homodimers and heterodimers and regulate gene expression by altering chromatin structure, by interacting directly with the components of the pre-initiation complex or by recruiting cofactors. These cofactors lack DBD but are able to activate or repress transcription by enhancing or inhibiting interactions between the DNA binding transcription factors and the preinitiation complex.
Peroxisomal inducers are a class of compounds that act as ligands to the steroid receptor family of peroxisomal Fig. 11 . Effect of a 6-week treatment with peroxisomal inducers on CoQ content in various organs. Data taken from Å berg et al. [251, 252] .
proliferator activated receptors (PPARa, h and g) [257] . When ligands bind to PPAR, it dimerizes with another receptor, the retinoid X receptor (RXRa, h and g) and the binding of the ligand -receptor complex to its cognate response element can activate or repress specific transcription [258] . PPARa affects genes including those encoding apolipoproteins, lipoprotein lipase, fatty acid transport protein, peroxisomal and mitochondrial fatty acid metabolizing enzymes and bile acid synthesizing enzymes [259 -261] . Several chemicals such as hypolipidemic drugs, phthalates and fatty acids can act as ligands to PPARa while the ligand to RXR is 9-cis retinoic acid. RXR is able to form heterodimers with a variety of hormone and orphan receptors [262 -265] . The dimerization partner includes RXR itself, the retinoic acid receptor, the vitamin D receptor, the thyroid hormone receptor, PPAR and orphan receptors. These heterodimers bind to direct repeat elements with spacings varying from one to five nucleotides [266] . RXR probably exists in cells as monomers in equilibrium with heterodimerized RXRs. Under in vivo conditions, the different nuclear hormone receptors compete for binding to RXR, bringing about a possible mechanism for crosstalk. Silencing of gene transcription can occur both in the absence of ligands and in the presence of additional co-repressors [267] .
Influence of PPAR and RXR on CoQ biosynthesis
The experiments performed with peroxisomal inducers clearly indicate that nuclear receptors are involved in the regulation of CoQ metabolism. By utilizing PPARa-null mice, it was possible to investigate the involvement of PPARa in activation of CoQ biosynthesis [253] . Disruption of the PPARa gene results in mice that are refractory to the pleiotropic responses to inducers, but does not exhibit any gross phenotypic defects [268] . Both the PPARa-null and wild-type mice had similar amounts of tissue CoQ and also cholesterol and dolichol [253] . Upon administration of DEHP, there was no induction of CoQ in the null mice. As described before, the rate of biosynthesis rather than the rate of breakdown was altered by administration of inducers [240] . Also trans-prenyltransferase and nonaprenyl-4-hydroxybenzoate transferase activities were up-regulated after peroxisomal induction in the wild type, but not in the PPARa-null mice. The induction of CoQ in different tissues followed the expression of PPARa in these tissues [269] . Since neither of these two genes nor their promoters are identified in mammals, it was not possible to investigate whether PPARa-RXR acted directly on the CoQ genes or if the response to peroxisomal inducers was indirect.
Recently, a hepatocyte-specific RXRa-deficient mouse (RXRa-def) was produced [270] . These mice are different from the PPARa-null mice in several aspects. RXRa deficiency results in an induction of mRNA for several apolipoproteins, serum cholesterol and triglyceride levels, which is not seen in the PPARa-null mice [271] . Investigations of these mice revealed that RXRa-def mice have only half of the CoQ concentration in the liver in comparison with the controls while both cholesterol and dolichol levels were unchanged [254] . Also, the RXRa-def mice have a decreased in vivo incorporation of [ 3 H]mevalonate into CoQ when compared to wild-type mice. On the other hand, the induction of hepatic CoQ after exposure to DEHP is present in the RXRa-def mice. In the kidney, which does not have a dysfunctional RXR, CoQ concentration and biosynthesis is equal to the control in all aspects.
Nuclear receptors are also involved in the CoQ induction upon cold exposure. PPARa-null mice had an increased amount of this lipid in the liver after cold treatment while the RXRa-def mice did not respond to the cold treatment [254] . These data further support the suggested presence of one or several response elements in the promoters of CoQ biosynthetic genes.
The role of nuclear receptors in CoQ metabolism is summarized in Table 7 . RXRa regulates the amount of CoQ in liver and probably is required for the basal transcription of genes involved in CoQ biosynthesis and for its induction upon cold treatment, however, it is not involved in the elevated biosynthesis during treatment with peroxisomal inducer. PPARa is neither required for the basal biosynthesis of the lipid nor for its induction by cold exposure, but is necessary for the increase at treatment with peroxisomal inducer. RXR is operating as a heterodimer, but we have at present no information on the exact nature of the other receptor. Some of the candidates are the liver X and farnesol X receptors since both are related to lipid metabolism associated with the mevalonate pathway. Further studies have to answer on a number of questions concerning the involvement of transcription factors in CoQ biosynthesis. It appears also that neither PPARa nor RXRa is involved in the basic synthesis of cholesterol and dolichol.
From E. coli to human
Almost all knowledge in the field of CoQ distribution, metabolism, synthesis and function originate from studies performed on bacteria, yeast, C. elegans and, to some limited extent, on rats. A single cell or less complex organism is always advantageous to identify and characterize cellular processes and in most cases it is the only way to 1. The metabolism of CoQ in higher organisms obviously differs in a great extent from that of single-cell organisms. Even if the synthesis and breakdown may follow a similar pattern, considerable differences are established concerning individual steps and, in particular, the regulation of these reactions. 2. In higher organisms the uptake of dietary CoQ is very limited under normal conditions and the uptake from the blood to the organs is also restricted, especially into mitochondria. In one-cell systems the uptake is not regulated by a complex mechanism but follows an uptake mechanism valid to most of lipids present in the environment. 3. Animal tissues have a number of efficient systems to reduce oxidized CoQ, which maintains a high antioxidant level. This is probably not the case in C. elegans, where dietary CoQ shortens life-span and, additionally, probably increases electron transport, resulting in release of ROS [272] . However, life-long administration of CoQ does not affect life-span of rats and mice [273, 274] . 4. Like other active cellular components, the action of CoQ is not restricted to only a few actions such as serving as redox mediator and antioxidant. CoQ interferes with h2-integrins and complement receptors of monocytes, changes hormone levels, affects uptake of a-T, may modify the production of leukotrienes and prostaglandins and regulates signaling systems by metabolites. In this way, contrary to single-cell organisms, a variety of metabolic interferences occur in mammals as a result of species-specific response.
Aging
Changes in lipid composition during aging are of great interest since these modifications have significant impact on the physico-chemical structure of membranes and function of the integral enzymes and their metabolic processes. The mevalonate pathway lipids display a characteristic behavior during aging [275] . In Table 8 , human heart and pancreas from a 2-day old newborns are compared with persons of age 20 and 80 years. The CoQ content is greatly increased in the first 20 years of life, followed by a decrease in a variable extent and in some organs at 80 years of age may be lower than at birth. Both dolichol and dolichyl-P increase during the whole life at a great extent. An important question that is not yet addressed is, however, to which extent these modifications represent a real deficiency in the membrane structure or are attributed to a change in cellular organization. Only a limited extent of decrease of CoQ content was observed in synaptic and non-synaptic mitochondria from different brain regions, and in mitochondria in liver and heart of rats during aging [276, 277] . Mitochondria prepared from tissues of aged mice do not exhibit changes in CoQ levels with the exception of skeletal muscle [278] . It would be of great importance to establish whether CoQ is decreased in individual cellular membranes or if the modification is the consequence of a decrease in number of mitochondria. CoQ in adult tissues is found mostly in reduced form but the extent of reduction in aged tissue is not yet determined. If the oxidized portion is increased, this may favor the catabolic activities leading to an accelerated breakdown and decrease in the amount of CoQ in the tissue.
Diseases
The CoQ content is altered in a number of diseases, of which the decrease in cardiomyopathies and degenerative muscle diseases are the most studied [279 -282] . CoQ is commonly used for treatment of cardiomyopathy and there is substantial evidence that heart function is improved upon administration of the lipid [283] . CoQ reaches the heart via the blood but is taken up only to a limited extent, and the uptake is probably not sufficient to account for all of the observed improvements. Other mechanisms, either of signaling type or production of mediators, appear to exist which do not require the entrance of CoQ into the cell.
Hyperplastic noduli is the first stage during development of chemically induced hepatocellular cancer in rat and during this first stage the amount of CoQ increases (Table  9 ) [284, 285] . Interestingly, the amount of CoQ in the mitochondria is stable, and the change in CoQ concentrations is attributed to the extra-mitochondrial compartments. During the first stage of the disease there is increased oxidative stress which has been suggested to induce an adaptive response, resulting in that the cell protects itself by raising the concentrations of antioxidants [286] . In the Heart  20  300  132  400  59  82  80  129  605  2364  82  109  Pancreas  20  228  5450  176  50  140  80  71  17,502  500  68  181 Data taken from Kalen et al. [275] .
noduli also dolichol and dolichyl-P levels are elevated. Upon progression of the disease, manifest cancer develops and the amount of CoQ decreases to only 40% in human and 76% in rat [287] (Olsson, J.M., unpublished data). Cholesterol is doubled in fully developed cancerous liver. In biopsy samples from human heart, a significant decrease of the CoQ content in cardiomyopathy was found and the decrease could be related to the severity of the disease [237 -239] . In these biopsy samples, uptake of CoQ was found after dietary treatment with the lipid.
CoQ has been suggested to be involved in neurodegenerative diseases such as Huntington's disease, Parkinson's disease and amyotrophic lateral sclerosis [288 -290] . In both experimental models and human patients, beneficial effects have been observed after supplementation with CoQ [291, 292] . Changes in lipid concentrations are extensive in Alzheimer's disease in humans and in scrapie-caused prion disease in mice [213, 293] . The amount of CoQ is greatly increased in both instances, especially in the prion disease, about 250%. a-T, the other main lipid-soluble antioxidant, is also increased under these conditions. It is now generally accepted that increased production of free radicals is an important feature during the development of these diseases, and it is not surprising that cellular protection is induced to counteract these radicals [294] . It has also been suggested that Alzheimer's and prion diseases-in spite of their different appearances-have much in common in etiology and development [295] . This possibility is further strengthened by the behavior of other mevalonate pathway lipids. In both diseases, dolichol decreases, dolichyl-P increases and cholesterol is unchanged throughout the process.
In a murine model of Niemann-Pick type C disease, there is a massive accumulation of cholesterol in the liver. In this disease dolichyl-P is greatly increased and CoQ is lowered in a significant extent [296] . In experimental diabetes, the concentration of CoQ in rat liver and in testis mitochondria is elevated [297, 298] . Statins are of great interest as the most commonly used drugs for treatment of hypercholesterolemia and it is recently established that they are additionally decreasing the level of inflammatory cytokines [299] . These drugs, however, have unwanted effects by not only lowering CoQ levels in the blood but also by causing other symptoms such as muscle disturbances [300] . The explanation is that statins interfere with various enzymatic steps of the mevalonate pathway lipid biosynthesis since CoQ, dolichol and dolichyl-P in heart and muscle are decreased upon treatment [192] .
The importance of CoQ in the life of the living organisms is illuminated most clearly by the number of reports describing the genetic disorders in which CoQ synthesis is impaired. Lowered lipid content in organs causes serious metabolic disturbances but CoQ supplementation reestablishes mitochondrial and other functions. Our primary goal in the near future should be to establish an animal model with deficiency of the biosynthetic system. Studies in such model could give valuable information on the physiological role of CoQ and answer questions concerning its complex involvement in various aspects of the living organism. 
